Why the study?
Does chronic NOS inhibition with L-NAME induce vascular and cardiac hypertrophy in Wistar-Kyoto rats?
Does chronic NOS inhibition with L-NAME induce vascular and cardiac hypertrophy in Wistar-Kyoto rats?
Chronic NO deficiency in vivo via NOS blockade results in the development of vascular smooth muscle cell polyploidy and true cardiomyocyte hypertrophy.
L-NAME-induced NO deficiency promotes VSMC polyploidy and cardiomyocyte hypertrophy in rats; leaves open mechanistic relevance to human hypertension.
To assess the vascular and cardiac response to NO (nitric oxide) synthase (NOS) blockade in vivo, Wistar-Kyoto rats (WKY) were treated for 3 wk with NG-nitro-L-arginine methyl ester (L-NAME; 10 mg.kg-1.day-1). L-NAME treatment induced hypertension that was associated with increased plasma renin activity. Flow cytometry cell cycle DNA analysis showed that aortic vascular smooth muscle cells (VSMC) from L-NAME-treated WKY had a significantly higher polyploid population compared with WKY controls. Using organ bath experiments, we have shown that aortic rings from L-NAME-treated WKY have an increased contractile response to phenylephrine and impaired relaxation to carbachol compared with control rings. NOS blockade in vivo caused a significant increase in cardiac and left ventricular hypertrophy. Northern mRNA analysis of the myocardium showed that L-NAME treatment caused reexpression of the fetal skeletal alpha-actin isoform without alterations in collagen type I expression, a pattern indicating true hypertrophy of the cardiomyocytes. These studies provide further insight to confirm that NO deficiency in vivo results in the development of vascular and cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Devlin et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: